API | lonafarnib

lonafarnib (Zokinvy) Report issue

Small molecule Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA Priority Review ^FDA

Active Ingredient History

NOW

Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha (Rattus norvegicus) ^UniProt
- Protein farnesyltransferase subunit beta (Rattus norvegicus) ^UniProt
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Progeria (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Hepatitis D (Phase 2)

Hepatitis D, Chronic (Phase 3)

Hepatitis Delta Virus (Phase 3)

Liver Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue